Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.76
- Piotroski Score 8.00
- Grade Hold
- Symbol (DVA)
- Company DaVita Inc.
- Price $154.44
- Changes Percentage (-1.81%)
- Change -$2.84
- Day Low $154.30
- Day High $157.56
- Year High $168.50
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $131.00
- High Stock Price Target $150.00
- Low Stock Price Target $90.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $8.82
- Trailing P/E Ratio 16.23
- Forward P/E Ratio 16.23
- P/E Growth 16.23
- Net Income $691.54 M
Income Statement
Quarterly
Annual
Latest News of DVA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Hyzon Motors Inc (HYZN) Q3 2024 Earnings Call Highlights: Fuel Cell Advancements and Strategic ...
The trucks' performance in trials has exceeded expectations, showing better fuel efficiency compared to diesel trucks. Initial delivery of Green Waste order could start in late 2025, involving steps l...
By Yahoo! Finance | 15 hours ago -
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...
Fulcrum Therapeutics plans to keep its new assets wholly-owned for now, focusing on inherited aplastic anemias. The company received positive feedback from the FDA for healthy volunteer studies on poc...
By Yahoo! Finance | 15 hours ago -
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
The CEO mentions that specific patient numbers and biomarker data for XMT-1660 will be shared later this year. The company is exploring more frequent dosing schedules and assessing prior treatment his...
By Yahoo! Finance | 15 hours ago
